Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : On Target Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUXâ„¢)
Details : Pafolacianine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Gastrointestinal Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 15, 2025
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : On Target Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : John Waters
Deal Size : Inapplicable
Deal Type : Inapplicable
CYTALUX (Pafolacianine) Single-Dose Pilot Study For Intraoperative Cancer Tissue Detection
Details : Pafolacianine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Esophageal Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 26, 2025
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : John Waters
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : On Target Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pafolacianine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gastrointestinal Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 19, 2024
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : On Target Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : On Target Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
CYTALUXâ„¢for the Intraoperative Imaging of Prostate Cancer
Details : Pafolacianine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : On Target Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : On Target Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
Details : Pafolacianine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteosarcoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 31, 2024
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : On Target Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cytalux (pafolacianine) is an FDA-approved optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.
Product Name : Cytalux
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 11, 2022
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Clinipace Worldwide
Deal Size : Inapplicable
Deal Type : Inapplicable
ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting
Details : OTL38 is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lung Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 27, 2020
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Clinipace Worldwide
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Details : OTL38 is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 08, 2017
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Medelis
Deal Size : Inapplicable
Deal Type : Inapplicable
OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
Details : OTL38 is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lung Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 19, 2016
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Medelis
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Details : OTL38 is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 16, 2014
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable